News / Blog
May Holidays 2023 - Pay Attention!
Beova tablets 50 mcg for urination problems (vibegron, Gemtesa)
Product Code :
Availability : 10
General information on Japanese Beova tablets 50 mcg for urination problems (vibegron, Gemtesa)
Package details: 100 tablets
Manufacturer: Kyorin Pharmaceuticals Co., Ltd., Kissei Pharmaceuticals Co., Ltd., Japan
Active ingredients: vibegron (chemical formula C26H28N4O3)
Medical effect: Beova tablets are effective for the treatment of following diseases and conditions:
- Overactive bladder,
- Urinary urgency,
- Frequent urination,
- Urinary incontinence.
Contraindications and precautions: do not use for pregnant or breastfeeding women.
If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.
Dosage and administration
For adults: take 1tablet (50 mcg of vibegron) once a day, after meal.
How effective are Beova tablets 50 mcg from Japan for urination problems (vibegron, Gemtesa)?
Beova tablets contain vibegran, a selective beta 3 adrenergic receptor agonist. It works by acting on beta 3 adrenergic receptors present in bladder and relaxing bladder smooth muscles. Consequently, Beova tablets help to accumulate urine in the bladder.
Who should use Beova tablets 50 mcg from Japan?
Beova tablets are effective for the treatment of overactive bladder and such its symptoms as urinary urgency, frequent urination and urinary incontinence. This medicine was developed in Japan by developed in Japan by Kyorin Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co.,Ltd and Urovant Sciences and approved for medical use in 2018. Studies showed that treatment with vibegron helps to reach a significant decrease in daily micturitions and number of urinary incontinence episodes (H. D. Mitcheson, S. Samanta. "Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial". European Urology, 2019, 75 (2): 274–282).